Baillie Gifford - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q1 2023$4,612
-13.4%
1150.0%0.00%
Q4 2022$5,328
+6.6%
1150.0%0.00%
Q3 2022$5,000
-28.6%
1150.0%0.00%
Q2 2022$7,000
-12.5%
1150.0%0.00%
Q1 2022$8,000
-20.0%
1150.0%0.00%
Q4 2021$10,0000.0%1150.0%0.00%
Q3 2021$10,000
-9.1%
1150.0%0.00%
Q2 2021$11,000
-15.4%
1150.0%0.00%
Q1 2021$13,000
-13.3%
115
+8.5%
0.00%
Q4 2020$15,0001060.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders